Daiichi Sankyo (DSNKY) News Today $22.65 -0.05 (-0.22%) As of 02/21/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Daiichi Sankyo (OTCMKTS:DSNKY) Hits New 52-Week Low - What's Next?Daiichi Sankyo (OTCMKTS:DSNKY) Hits New 12-Month Low - What's Next?February 20 at 5:58 PM | marketbeat.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Increase in Short InterestDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 65,000 shares, a growth of 91.7% from the January 15th total of 33,900 shares. Based on an average daily volume of 471,700 shares, the short-interest ratio is currently 0.1 days.February 15, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Hits New 1-Year Low - Should You Sell?Daiichi Sankyo (OTCMKTS:DSNKY) Hits New 12-Month Low - Here's WhyFebruary 12, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Hits New 12-Month Low - What's Next?Daiichi Sankyo (OTCMKTS:DSNKY) Hits New 12-Month Low - Should You Sell?February 10, 2025 | marketbeat.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest UpdateDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 33,900 shares, a drop of 38.1% from the December 31st total of 54,800 shares. Based on an average trading volume of 343,700 shares, the days-to-cover ratio is presently 0.1 days.February 3, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Announces Quarterly Earnings ResultsDaiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.22 earnings per share (EPS) for the quarter.January 31, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Updates FY 2024 Earnings GuidanceDaiichi Sankyo (OTCMKTS:DSNKY) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.840-0.840 for the period.January 31, 2025 | marketbeat.comDaiichi Sankyo Appoints Hiroyuki Okuzawa To Succeed Sunao Manabe As CEOJanuary 31, 2025 | markets.businessinsider.comDaiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive OfficerJanuary 30, 2025 | businesswire.comFDA Approves AstraZeneca And Daiichi Sankyo's ENHERTU For HER2-Low/Ultralow Breast CancerJanuary 27, 2025 | markets.businessinsider.comDaiichi Sankyo’s Growth Prospects Bolstered by FDA Approval of Dato-DXd and Upcoming CatalystsJanuary 24, 2025 | markets.businessinsider.comDaiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer DrugJanuary 20, 2025 | marketwatch.comFDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast CancerJanuary 18, 2025 | markets.businessinsider.comDaiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mJanuary 15, 2025 | msn.comDaiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbHJanuary 13, 2025 | uk.finance.yahoo.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Growth in Short InterestDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY - Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 54,800 shares, a growth of 896.4% from the December 15th total of 5,500 shares. Based on an average trading volume of 573,800 shares, the days-to-cover ratio is presently 0.1 days.January 13, 2025 | marketbeat.comDatopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerJanuary 13, 2025 | finance.yahoo.comHigh Expectations And Data Disappointments Have Driven Daiichi Sankyo LowerJanuary 10, 2025 | seekingalpha.comDaiichi Sankyo gets Japanese approval for DatrowayDecember 28, 2024 | msn.comAstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EUDecember 24, 2024 | markets.businessinsider.comAstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EUDecember 24, 2024 | marketwatch.comAstraZeneca And Daiichi Sankyo Withdraw EU Marketing Application For Datopotamab DeruxtecanDecember 24, 2024 | markets.businessinsider.comDaiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third timeNovember 20, 2024 | msn.comDaiichi Sankyo’s Strategic Advancements and Innovative ADC Developments Drive Buy RatingNovember 13, 2024 | markets.businessinsider.comDaiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOSNovember 13, 2024 | finance.yahoo.comAstraZeneca, Daiichi Sankyo sumbit new BLA for datopotamab deruxtecanNovember 12, 2024 | markets.businessinsider.comAlteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ TechnologyNovember 10, 2024 | finance.yahoo.comAlteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU DevelopmentNovember 10, 2024 | markets.businessinsider.comENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology ProductNovember 8, 2024 | finance.yahoo.comBernstein Reaffirms Their Buy Rating on Daiichi Sankyo Company (DSKYF)November 1, 2024 | markets.businessinsider.comThree Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung CancerOctober 30, 2024 | finance.yahoo.comDaiichi Sankyo to Boost ADC Cancer Drug Production, COO SaysOctober 10, 2024 | bloomberg.comDaiichi Sankyo Co (OTC:DSNKY) Stock Quotes, Forecast and News SummarySeptember 18, 2024 | benzinga.comDaiichi Sankyo: Showing No Signs Of Slowing Down ADC DominanceSeptember 18, 2024 | seekingalpha.comDaiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 StudySeptember 17, 2024 | markets.businessinsider.comAstraZeneca, Roche cut at Deutsche after trial readouts for key drugsSeptember 13, 2024 | seekingalpha.comIs Merck Stock Undervalued After Its Colossal Earnings Growth? (DSNKY)Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant?September 13, 2024 | marketbeat.comAstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming DataSeptember 12, 2024 | seekingalpha.comDaiichi Sankyo Plunges on Mixed Trial Result of Lung Cancer DrugSeptember 10, 2024 | bloomberg.comMerck, Daiichi post mid-stage data for novel lung cancer drugSeptember 7, 2024 | msn.comENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast CancerAugust 19, 2024 | finance.yahoo.comDSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024August 13, 2024 | investorplace.comMerck, Daiichi Sankyo Add Merck's MK-6070 to CollaborationAugust 6, 2024 | marketwatch.comMerck, Daiichi Sankyo expand cancer drug dealAugust 6, 2024 | msn.comDaiichi Sankyo Co Ltd ADR (DSNKY)August 5, 2024 | in.investing.comHere's what Wall Street expects from DAIICHI SANKYO's earnings reportJuly 30, 2024 | markets.businessinsider.comDaiichi Sankyo Opens New Affiliate for Oncology in GreeceJuly 10, 2024 | businesswire.comAstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in PatientsMay 27, 2024 | marketwatch.comDaiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCOMay 21, 2024 | finance.yahoo.comHeart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock SoarsMay 7, 2024 | finance.yahoo.com Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address DSNKY Media Mentions By Week DSNKY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSNKY News Sentiment▼-0.580.60▲Average Medical News Sentiment DSNKY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSNKY Articles This Week▼11▲DSNKY Articles Average Week Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sanofi News Today GSK News Today Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:DSNKY) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Company, Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Daiichi Sankyo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DSNKY Stock Alerts